Concourse Financial Group Securities, Inc. Intellia Therapeutics, Inc. Transaction History
Concourse Financial Group Securities, Inc.
- $1.52 Billion
- Q1 2024
A detailed history of Concourse Financial Group Securities, Inc. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Concourse Financial Group Securities, Inc. holds 1,341 shares of NTLA stock, worth $29,703. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,341
Previous 604
122.02%
Holding current value
$29,703
Previous $18,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding NTLA
# of Institutions
313Shares Held
89.3MCall Options Held
686KPut Options Held
599K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl11MShares$243 Million2.16% of portfolio
-
Black Rock Inc. New York, NY9.11MShares$202 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.09MShares$201 Million0.01% of portfolio
-
State Street Corp Boston, MA4.6MShares$102 Million0.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.21MShares$93.3 Million3.83% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $1.68B
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...